Table 2.
Geometric mean (95% CI) of blood arsenic (μg/L) and the percent change in blood arsenic from baseline to week 12 by first phase treatment group.
| Time or time comparison | Statistic | Placebo | FA400 (μg) | FA800 (μg) | Creatine | Creatine+FA400 (μg) |
|---|---|---|---|---|---|---|
| Baseline | Mean (95% CI) | 8.32 (7.42, 9.32) (n = 102) | 8.73 (7.89, 9.66) (n = 153) | 8.72 (8.00, 9.50) (n = 151) | 8.73 (7.72, 9.87) (n = 101) | 9.26 (8.38, 10.24) (n = 103) |
| Week 1 | Mean (95% CI) | 6.40 (5.74, 7.14) (n = 102) | 6.88 (6.18, 7.66) (n = 151) | 6.20 (5.71, 6.74) (n = 151) | 6.54 (5.83, 7.33) (n = 101) | 6.84 (6.18, 7.58) (n = 102) |
| Week 6 | Mean (95% CI) | 6.20 (5.43, 7.09) (n = 102) | 6.93 (6.17, 7.79) (n = 153) | 5.86 (5.33, 6.43) (n = 151) | 6.70 (5.92, 7.59) (n = 101) | 7.09 (6.28, 8.01) (n = 103) |
| Week 12 | Mean (95% CI) | 7.62 (6.72, 8.64) (n = 101) | 8.40 (7.55, 9.36) (n = 153) | 7.19 (6.56, 7.87) (n = 150) | 8.12 (7.20, 9.15) (n = 101) | 7.96 (7.04, 9.00) (n = 103) |
| Week 1 vs. baseline | Percent change (95% CI)a | –23.0 (–26.6, –19.3) (n = 102) | –21.2 (–24.4, –17.8) (n = 151) | –28.9 (–31.8, –25.8) (n = 151) | –25.1 (–28.6, –21.4) (n = 101) | –25.6 (–29.7, –21.2) (n = 102) |
| Week 6 vs. baseline | Percent change (95% CI) | –25.4 (–31.5, –18.8) (n = 102) | –20.6 (–26.3, –14.5) (n = 153) | –32.8 (–38.0, –27.3) (n = 151) | –23.2 (–29.5, –16.3) (n = 101) | –23.5 (–30.8, –15.3) (n = 103) |
| Week 12 vs. baseline | Percent change (95% CI) | –9.5 (–16.5, –1.8) (n = 101) | –3.7 (–10.7, 3.8) (n = 153) | –17.8 (–25.0, –9.8) (n = 150) | –7.0 (–14.8, 1.5) (n = 101) | –14.0 (–22.2, –5.0) (n = 103) |
| aPercent change = (geometric mean ratio – 1) × 100. | ||||||